June 26, 2024 - First-in-Class Suppressor of the TLR Pathway (Oral, Small Molecule IRAK4 Kinase Inhibitor) Innate immune responses orchestrated through Toll-like receptors or certain interleukin receptors are important mediators of the body’s initial defense against foreign antigens, while their dysregulation ...

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene’s compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC ...

7016 Background: CA-4948 is a novel oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) and FLT3. IRAK4 is critical in triggering inflammation, oncogenesis, and survival of cancer cells. Genetic mutations in the splicing factors SF3B1 and U2AF1 drive overexpression of a highly ...

National Cancer Institute at the National Institutes of Health

An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier and their unique microenvironment. These challenges are most evident in cancers such as ...

January 17, 2022 - CA-4948 S-Isomer is the S-Isomer of CA-4948. CA-4948 is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK... Quality confirmed by NMR & HPLC. See customer reviews, validations & product citations.

ASCO’s publications—including the Society’s flagship publication, the Journal of Clinical Oncology—serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the delivery of high-quality patient care across the ...

May 23, 2023 - Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic…

IntroductionCA-4948 is a novel oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is part of the Myddosome sig…

About Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. We currently have three drug candidates in development: Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of ...

November 5, 2020 - IntroductionCA-4948 is a novel oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is part of the Myddosome signalin

CA-4948: An IRAK-4 inhibitor. CAS Number: 1801343-74-7. Purity: ≥98%.

Full Title An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma Purpose The purpose of this study ...

December 1, 2021 - CA-4948 is an oral first-in-class small molecule inhibitor of IRAK4 that has demonstrated clinical activity in patients with systemic Non-Hodgkin’s Lymphoma. Our study goal was to evaluate CA-4948 efficacy in a syngeneic preclinical model of primary CNS B cell lymphoma (A20), supporting future ...

December 10, 2023 - The safety, clinical activity, ... (NCT04278768). Here we present preliminary safety and efficacy data in the subset of enrolled AML patients who carried FLT3 mutation (FLT3m) at baseline and were treated with emavusertib monotherapy....

CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 is a potent IRAK4/FLT3 inhibitor with ...

December 1, 2021 - IRAK4 is a protein kinase downstream the Toll-like receptor signaling. CA-4948 is the first-in-class inhibitor of IRAK4 and it is in phase 1/2 studies for patients with relapsed/refractory clinical studies with favorable activity in lymphomas and myeloid neoplasms.

July 1, 2017 - To functionally determine the role of IRAK4 in MDS/AML pathogenesis, we utilized CA-4948, a potent, oral, small-molecule inhibitor of IRAK4, to assess the effect of inhibiting IRAK4 catalytic activity. In vitro, CA-4948 blocked downstream NF-κB pathway signaling, including secretion of ...